News/ News/ R&D TargED Bio raises €39m for new clot-busting drug Phil Taylor acquired thrombotic thrombocytopenic purpura, cardiovascular, rare disease, stroke, TargED Biopharmaceuticals, thrombolysis 0 Comment There’s been hardly any change in the use of clot-dissolving (thrombolytic) therapies for conditions like heart attack and Share X TargED Bio raises €39m for new clot-busting drug https://pharmaphorum.com/news/targed-bio-raises-e39m-for-new-clot-busting-drug/